Sebastian Kobold

Division of Clinical Pharmacology, LMU University Hospital

Affiliated withLMU University Hospital German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ and the University Hospital of the LMU German Center for Lung Research (DZL)

Research Area

Immunology and Infection

Biography

Sebastian Kobold has not added Biography.
If you are Sebastian Kobold and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
ESCRT machinery: role of membrane repair mechanisms in escaping cell death. Signal transduction and targeted therapy\| PubMed ID: 35842417	2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumor... Journal for immunotherapy of cancer\| PubMed ID: 35902133	2022
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. The New England journal of medicine\| PubMed ID: 35947720	2022
Transwell migration assay to interrogate human CAR-T cell chemotaxis. STAR protocols\| PubMed ID: 36136753	2022
Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment. Seminars in immunopathology\| PubMed ID: 36167831	2023
Impact of the selective A2R and A2R dual antagonist AB928/etrumadenant on CAR T cell function. British journal of cancer\| PubMed ID: 36266575	2022
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models. Cellular oncology (Dordrecht, Netherlands)\| PubMed ID: 36409438	2023
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity\| PubMed ID: 36630913	2023
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nature biotechnology\| PubMed ID: 36914885	2023
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma. Journal for immunotherapy of cancer\| PubMed ID: 37208128	2023
Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control. International journal of cancer\| PubMed ID: 37350095	2023
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. British journal of cancer\| PubMed ID: 37400680	2023
Programmable multispecific DNA-origami-based T-cell engagers. Nature nanotechnology\| PubMed ID: 37591933	2023
Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology. Frontiers in immunology\| PubMed ID: 38045693	2023
Mutation-specific CAR T cells as precision therapy for IGLV3-21 expressing high-risk chronic lymphocytic leukemia. Nature communications\| PubMed ID: 38307904	2024
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma. Cancer immunology, immunotherapy : CII\| PubMed ID: 38630291	2024
PGE limits effector expansion of tumour-infiltrating stem-like CD8 T cells. Nature\| PubMed ID: 38658748	2024
Multiomic analyses uncover immunological signatures in acute and chronic coronary syndromes. Nature medicine\| PubMed ID: 38773340	2024
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity. Cancers\| PubMed ID: 39061247	2024
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy\| PubMed ID: 39080180	2024
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis. Cancer immunology, immunotherapy : CII\| PubMed ID: 39358663	2024
RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 39625823	2025
Sex-dependent modulation of T and NK cells and gut microbiome by low sodium diet in patients with primary aldosteronism. Frontiers in immunology\| PubMed ID: 39749333	2024
Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma. HemaSphere\| PubMed ID: 39807276	2025
Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research. Methods in cell biology\| PubMed ID: 39824562	2025
Steroid hormones as modulators of anti-tumoural immunity. Nature reviews. Endocrinology\| PubMed ID: 40128599	2025
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood\| PubMed ID: 40178843	2025
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors. Cancer research\| PubMed ID: 40305099	2025
Novel approaches to CAR T cell target identification in acute myeloid leukemia. Current opinion in pharmacology\| PubMed ID: 40311558	2025
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection. PloS one\| PubMed ID: 40498720	2025
CSF1R myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer cell\| PubMed ID: 40513575	2025
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. Journal for immunotherapy of cancer\| PubMed ID: 40514065	2025
Metabolites as agents and targets for cancer immunotherapy. Nature reviews. Drug discovery\| PubMed ID: 40571788	2025
Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy. Signal transduction and targeted therapy\| PubMed ID: 40640140	2025
11th Immunotherapy of Cancer conference (ITOC): A meeting report. Human vaccines & immunotherapeutics\| PubMed ID: 40679247	2025
Ultra-high-scale cytometry-based cellular interaction mapping. Nature methods\| PubMed ID: 40775086	2025
Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines. Research square\| PubMed ID: 41282134	2025
CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases. Blood reviews\| PubMed ID: 41318274	2025
FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion. Blood advances\| PubMed ID: 41324594	2025